News|Articles|July 27, 2026

Dosing begins in phase 2a/2b trial of YB-101 after Yarrow Bioscience closes merger with VYNE Therapeutics

A study of YB-101, a potential treatment for both Graves' disease and thyroid eye disease, has begun dosing the first patients. The molecule receive Fast Track Designation from the FDA.

Yarrow Bioscience announced in a press release that it closed its merger with VYNE Therapeutics and dosing of patients began in a phase 2a/b trial (NCT07682896) of Graves’ disease (GD) and thyroid eye disease (TED). YB-101 has received Fast Track Designation from the FDA.